|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the roles of ATGL in cancer are still neglected though a putative tumour suppressor function of ATGL has been envisaged, as its expression is frequently reduced in different human cancers (e.g., lung, muscle, and pancreas).
|
29472527 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chi-squared testing revealed a statistically significant association between high ATGL expression and both BMI >25 kg/m<sup>2</sup> (χ<sup>2</sup>=5.74, p=0.017) and increased tumor stroma (χ<sup>2</sup>=19.14, p<0.001).
|
28179319 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, ATGL is expressed in human tumors where its expression correlates with tumor aggressiveness and is upregulated by contact with adipocytes.
|
28239646 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results, therefore, suggest a novel tumor suppressor function for ATGL and contribute to the understanding of cancer metabolism.
|
27213586 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Genes associated with β-oxidation (peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1A, and hydroxyacyl-CoA dehydrogenase), lipoprotein excretion (apolipoprotein B, microsomal triglyceride transfer protein, and acyl-CoA:cholesterol acyltransferase 2), fatty acid transport (fatty acid-binding protein), construction of triglycerides in the endoplasmic reticulum (acyl-CoA:diacylglycerol acyltransferase 1), and LD degradation/lipolysis (comparative gene identification-58, adipose triglyceride lipase) were significantly downregulated in neoplasms compared with non-tumor areas.
|
26513060 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of adipose triglyceride lipase (ATGL) by the putative tumor suppressor G0S2 or a small molecule inhibitor attenuates the growth of cancer cells.
|
26318046 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pigment epithelium-derived factor (PEDF), a potent antiangiogenesis agent, has recently attracted attention for targeting tumor cells in several types of tumors.
|
25225287 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we evaluated the feasibility of using hMSCs (human mesenchymal stem cells) to deliver PEDF (pigment epithelium-derived factor), a potent inhibitor of tumour angiogenesis, in a model of intracranial gliomas.
|
22917444 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo antitumor activity results showed that CSOSA-g-PEI/plasmid pigment epithelium-derived factor formulation could effectively suppress the tumor growth (above 60% tumor inhibition) without systematic toxicity against animal body after intravenous injection.
|
22951455 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have recently demonstrated that a 4-in-1 gene therapy strategy that contains two anti-angiogenic genes [endostatin and pigment epithelium-derived factor] and two cytokine genes [granulocyte macrophage colony-stimulating factor and interleukin 12] has a considerable antitumor effect on large tumors in a woodchuck hepatoma model.
|
22266191 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pigment epithelium- derived factor remarkably suppressed the growth of NPC by 43.52% and decreased the tumor microvessel density (MVD).
|
21707863 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we report on an in situ gelling chitosan-based hydrogel system that sustains the release of a potential anti-cancer gene (pigment epithelium-derived factor) to the tumor site.
|
19505719 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model.
|
16857775 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor.
|
12842430 |
2003 |